Home » Newsletters » BioWorld Science

BioWorld Science

July 16, 2015

View Archived Issues

Dendritic cell vaccination induces tumor-specific immune responses

China Food and Drug Administration accepts clinical trial application for sirotinib

ONO-7750512 shows potent antithrombotic effect without increasing bleeding risk

Bristol-Myers Squibb provides update on pipeline for fibrotic diseases

Aerpio Therapeutics reports data from phase IIa study of AKB-9778 in DME

CytoDyn reports evidence of HIV suppression with PRO-140

Pharmacological profile a novel FXIa inhibitor from Sumitomo Dainippon presented

Initiation of phase II study of Ad26.ZEBOV and MVA-BN-Filo Ebola prime-boost vaccine regimen

Esteve discloses sigma1-receptor ligands

Wee1-like protein kinase inhibitors in early development at Almac Discovery

A*STAR patent describes Wnt signaling inhibitors

BTK inhibitors described in Merck & Co. patent

IRM divulges antiparasitic agents

Santen launches Ikervis in Germany for keratitis in dry eye disease

FDA grants orphan drug designation to DPX-Survivac for ovarian cancer

ValiRx announces plans for phase II trial of VAL-401

Treeway and collaborators receive grant to develop edaravone for ALS

Nanocarrier formulation improves delivery of CsA to the eye

FDA gives orphan drug designation to Kevetrin for ovarian cancer

AB Science initiates phase II/III trial of masitinib in ovarian cancer

Cerenis releases results from LOCATION study of CER-001 in atherosclerotic disease

AstraZeneca enters into commercialization option agreement for benralizumab in Japan

Celgene to acquire Receptos

ErepoXen increases hemoglobin levels to therapeutic range in phase II trial

Swedish Orphan Biovitrum exercises Alprolix opt-in right

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Latus Bio series A financing supports early-stage programs
BioWorld Science
Latus Bio Inc. has closed a $97 million series A financing to support its broad therapeutics pipeline based on novel AAV capsid variants. Proceeds from the...